Evidence-based guidelines for empirical therapy of neutropenic fever in Korea.
about
Hematologic diseases: high risk of Clostridium difficile associated diarrheaPatterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOPClinical characteristics and antimicrobial susceptibilities of viridans streptococcal bacteremia during febrile neutropenia in patients with hematologic malignancies: a comparison between adults and children.Impact of vancomycin resistance on mortality in neutropenic patients with enterococcal bloodstream infection: a retrospective study.Stenotrophomonas maltophilia bloodstream infection in patients with hematologic malignancies: a retrospective study and in vitro activities of antimicrobial combinations.Tuberculosis before hematopoietic stem cell transplantation in patients with hematologic diseases: report of a single-center experienceSerum galactomannan index for early prediction of mortality in immunocompromised children with invasive pulmonary aspergillosis.The demanding attention of tuberculosis in allogeneic hematopoietic stem cell transplantation recipients: High incidence compared with general populationRisk factors for febrile neutropenia during chemotherapy for HIV-related lymphoma.Posaconazole treatment in Korea: single-center experience over 5 years.Epidemiology and clinical features of bloodstream infections in hematology wards: one year experience at the catholic blood and marrow transplantation center.Clinical outcomes and prognostic factors of empirical antifungal therapy with itraconazole in the patients with hematological malignancies: a prospective multicenter observational study in Korea.Success rate and risk factors for failure of empirical antifungal therapy with itraconazole in patients with hematological malignancies: a multicenter, prospective, open-label, observational study in KoreaComparison of the QuantiFERON-TB Gold In-Tube test with the tuberculin skin test for detecting latent tuberculosis infection prior to hematopoietic stem cell transplantation.Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation.Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.Impact of time to antibiotics on outcomes of chemotherapy-induced febrile neutropenia.Risk factors and clinical outcomes of breakthrough yeast bloodstream infections in patients with hematological malignancies in the era of newer antifungal agents.Clinical characteristics and antibiotic susceptibility of viridans streptococcal bacteremia in children with febrile neutropenia.Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum β-lactamase production and its impact on outcome.Risk factors and prophylaxis against invasive fungal disease for haematology and stem cell transplant recipients: an evolving field.Breakthrough invasive fungal diseases during voriconazole treatment for aspergillosis: A 5-year retrospective cohort study.Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations.A new prognostic model for chemotherapy-induced febrile neutropenia.Invasive Pulmonary Aspergillosis-mimicking Tuberculosis.Collaborative Pharmacokinetic-Pharmacodynamic Research for Optimization of Antimicrobial TherapyTool for guidance: evidence-based recommendations for managing febrile neutropenia.The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylaxCharacteristics of culture-positive invasive pulmonary aspergillosis in patients with hematologic diseases: Comparison between Aspergillus fumigatus and non-fumigatus Aspergillus species.Infectious complications after hematopoietic stem cell transplantation: current status and future perspectives in Korea.Effect of an intervention targeting inappropriate continued empirical parenteral vancomycin use: a quasi-experimental study in a region of high MRSA prevalence.Comparison of Enterococcus faecium Bacteremic Isolates from Hematologic and Non-hematologic Patients: Differences in Antimicrobial Resistance and Molecular Characteristics.
P2860
Q33718326-0564798F-CF52-48E4-A33C-77F544EAFA0BQ34528537-753A9FD4-E6AD-48BA-B41C-59DC3029794BQ34774820-51596305-06B4-4B36-8E24-C88E0D83E933Q35027260-EB123A0D-CD54-41DA-A971-20735D5C0BD6Q35108518-52A11E35-32ED-4401-89DF-A88EFD3F0EACQ35134234-7C16A3EB-B3DE-4833-8CB6-4C3CED687C40Q35689788-B05F9E56-8A13-4EAB-8B45-14C3D2A5BC79Q36302252-E3514197-2E6A-44EF-AD81-8E9CC2E6B0B4Q36472941-596BC3BC-B2CA-4796-8235-03C129806EC3Q37094649-F14C48BA-C6C0-42E8-8397-395CEC094D27Q37192118-3C91EC80-E83B-4AD9-84DC-FBC30CCF1E22Q37418841-C355B8BB-EF02-4B5C-9F6B-05FAD64F9433Q37473671-B3F6BA55-4C2B-4E23-B650-1AC64E64F924Q38460302-7D5493DC-FE4C-4B7E-B8E0-E6398B8BCD8AQ39196770-C6B9AD4B-2B80-44EA-B5A1-EBDDFCC17A59Q40131663-98ACE419-D379-4ABF-BA54-F514A8B10C12Q40170349-8E50B396-50D0-4233-A7B6-871927B6568EQ40205895-CFA0E313-7861-4898-AFA6-EF6FC270957EQ40248953-C330E7A6-2EE4-4D80-98BA-2BBD86DEFDD4Q40267702-2E350011-17F3-42E5-98FF-DCABC6312407Q40515140-9337B66C-B91F-4672-A4C2-BBF0F1450AE3Q40562624-6180982C-F425-4361-987B-723F2CE8BDC1Q40691888-2ABA4ACC-2B13-486B-B01F-DBA5ADF5E4ADQ41180338-22489FE3-679F-4D60-95AE-22A923559AACQ41426371-6158447C-00DF-4208-8814-39C334EBEF86Q42388163-5E94A3AE-19AB-46A9-A4F7-06F632903196Q42750145-3961FD25-7B7A-4054-8290-993C98E6ECE9Q43600554-51921ADF-1152-4D13-BEB3-717BFC6118BBQ46240270-34F25EF9-D8BC-4E7F-ADAA-100756FD758CQ52728829-47BB00E3-B37A-4C76-8548-55F214BBB7CAQ53073487-DFEEE9CD-6473-4FA3-A12E-315BCCF47E18Q53083816-06DB6CD2-FA8F-46E8-BE51-CBDB90ACB141
P2860
Evidence-based guidelines for empirical therapy of neutropenic fever in Korea.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Evidence-based guidelines for empirical therapy of neutropenic fever in Korea.
@ast
Evidence-based guidelines for empirical therapy of neutropenic fever in Korea.
@en
type
label
Evidence-based guidelines for empirical therapy of neutropenic fever in Korea.
@ast
Evidence-based guidelines for empirical therapy of neutropenic fever in Korea.
@en
prefLabel
Evidence-based guidelines for empirical therapy of neutropenic fever in Korea.
@ast
Evidence-based guidelines for empirical therapy of neutropenic fever in Korea.
@en
P2093
P2860
P1476
Evidence-based guidelines for empirical therapy of neutropenic fever in Korea.
@en
P2093
Chung-Jong Kim
Jung-Hyun Choi
Soo Young Kim
Sung-Han Kim
Young Goo Song
P2860
P304
P356
10.3904/KJIM.2011.26.2.220
P577
2011-06-01T00:00:00Z